Clinical trial NCT00888836 - References

Type 2 Diabetes — Diet and Medical Therapy Versus Bariatric Surgery in Type 2 Diabetes

Citation(s)

•   Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V
  Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003 Aug;26(8):2231-7.
•   Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL
  Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004 Jan;70(1):1-4; discussion 4-5.
•   Cowan GS Jr, Buffington CK
  Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998 Sep;22(9):987-92.
•   Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA
  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005 Jan;90(1):493-500. Epub 2004 Oct 13.
•   Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, Mari A, DeFronzo RA
  Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003 Sep;46(9):1211-9. Epub 2003 Jul 23.
•   Ferrannini E
  Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998 Aug;19(4):477-90. Review.
•   Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E
  Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes. 2002 Jan;51(1):144-51.
•   Grill V, Björklund A
  Dysfunctional insulin secretion in type 2 diabetes: role of metabolic abnormalities. Cell Mol Life Sci. 2000 Mar;57(3):429-40. Review.
•   Hickey MS, Pories WJ, MacDonald KG Jr, Cory KA, Dohm GL, Swanson MS, Israel RG, Barakat HA, Considine RV, Caro JF, Houmard JA
  A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998 May;227(5):637-43; discussion 643-4.
•   Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E
  Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997 Sep;20(9):1353-6.
•   Jorde R, Burhol PG, Johnson JA
  The effect of jejunoileal bypass on postprandial release of plasma gastric inhibitory polypeptide (GIP). Scand J Gastroenterol. 1981;16(2):313-9.
•   Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al
  Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993 Nov;42(11):1663-72.
•   Kärvestedt L, Andersson G, Efendic S, Grill V
  A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med. 2002 Apr;251(4):307-16.
•   Lauritsen KB, Christensen KC, Stokholm KH
  Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass. Scand J Gastroenterol. 1980;15(4):489-95.
•   le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR
  Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006 Jan;243(1):108-14.
•   Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M, Biron S
  Biliopancreatic diversion with duodenal switch. World J Surg. 1998 Sep;22(9):947-54.
•   Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, Ferrannini E
  Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia. 2006 Sep;49(9):2136-43. Epub 2006 Jul 4.
•   Morínigo R, Moizé V, Musri M, Lacy AM, Navarro S, Marín JL, Delgado S, Casamitjana R, Vidal J
  Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006 May;91(5):1735-40. Epub 2006 Feb 14.
•   Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E
  Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005 Jan;118(1):51-7.
•   Näslund E, Backman L, Holst JJ, Theodorsson E, Hellström PM
  Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg. 1998 Jun;8(3):253-60.
•   Rossetti L, Giaccari A, DeFronzo RA
  Glucose toxicity. Diabetes Care. 1990 Jun;13(6):610-30. Review.
•   Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E
  The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004 Aug;240(2):236-42.
•   Rubino F, Marescaux J
  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004 Jan;239(1):1-11.
•   Ryan EA, Imes S, Wallace C
  Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004 May;27(5):1028-32.
•   Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G
  First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009 Mar;32(3):375-80. doi: 10.2337/dc08-1314. Epub 2008 Nov 25.
•   Sarson DL, Scopinaro N, Bloom SR
  Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes. 1981;5(5):471-80.
•   Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A
  Biliopancreatic diversion. World J Surg. 1998 Sep;22(9):936-46.
•   Sirinek KR, O'Dorisio TM, Hill D, McFee AS
  Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery. 1986 Oct;100(4):781-7.
•   Valverde I, Puente J, Martín-Duce A, Molina L, Lozano O, Sancho V, Malaisse WJ, Villanueva-Peñacarrillo ML
  Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005 Mar;15(3):387-97.
•   Weyer C, Tataranni PA, Bogardus C, Pratley RE
  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001 Jan;24(1):89-94.

Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI > 35 vs. Medical Therapy

Details for clinical trial NCT00888836